( * Seventy-eight percent (n=28/36) of...)Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients,Health

* Seventy-eight percent (n=28/36) of patients taking BARACLUDE and 82
percent (n=27/33) of patients taking adefovir experienced an adverse
event. The most common adverse events occurring in greater than 10
percent of patients in either treatment group were back pain, headache,
influenza, nasopharyngitis, fever, upper respiratory tract infection,
and urinary tract infection.

* Six percent (n=2/36) of patients taking BARACLUDE and 15 percent
(n=5/33) of patients taking adefovir experienced a Grade 3-4 adverse
event.

* Three percent (n=1/36) of patients taking BARACLUDE experienced a
serious adverse event (elevated ALT that resolved with continued
treatment). Nine percent (n=3/33) of patients taking adefovir
experienced a serious adverse event (one patient had elevated ALT that
resolved with continued treatment; one patient had acute hepatitis with
ALT flare [ALT flare defined as greater than two times baseline and
greater than 10 times the upper limit of normal]; one patient was
involved in a motor vehicle accident).

* There were no deaths in either arm and one patient discontinued
treatment due to an adverse event.

About BARACLUDE(R) (entecavir)Discovered at Bristol-Myers Squibb, BARACLUDE(R) (entecavir) is a nucleoside analogue indicated for the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication with either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. BARACLUDE has been approved in more than 60 countries and regions around the world.

Important Information About BARACLUDE(R) (entecavir) 0.5mg/1mg Tablets

BARACLUDE(R) (entecavir) is a prescription medicine used for chronic infection with hepatitis B virus (HBV) in adults
'"/>

Page: 1 2 3 4 5 6
Related medicine technology :

1. Baraclude (entecavir) Therapy Resulted in Undetectable Levels of Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment
2. Point of Care Strep Tests Speed Treatment, Lower Costs
3. Rapid HIV Testing Increases Possibility of Treatment
4. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
5. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
8. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
9. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
10. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
11. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease